Abstract: An enzyme electrode that enables rapid degradation of bisphenol-A (BPA) in a contaminated sample and/or monitoring of BPA concentration in a contaminated sample. The enzyme electrode includes a working electrode having one or more selected enzymes that are capable of degrading BPA linked to the working electrode. The selected enzymes linked to the working electrode are capable of degrading BPA at an enhanced rate in response to an applied voltage. The electrode can be used to monitor BPA concentration in a contaminated sample by measuring current flow through the electrode in response to an applied voltage.

Abstract: A DNA intercalator detection system can include a filtration unit and control sample conditioner operably coupled with the filtration unit and an analytic unit operably coupled with the filtration unit and control sample conditioner and having an electronic chemical array (ECA) reaction component. A data processing unit is operably coupled with the analytic unit and configured to compare and determine a difference between electronic data of a test sample and a conditioned control sample from the ECA reaction component. The difference provides an indication of whether or not a DNA intercalator is present in the test sample.

Abstract: A fingerprint authentication apparatus and a fingerprint authentication method are provided. The fingerprint authentication apparatus is configured to prevent infection from viruses or bacteria and quickly and accurately perform fingerprint authentication. The fingerprint authentication apparatus includes an irradiation section that irradiates a mounting section when a finger is not detected to prevent infection.

Abstract: A DNA intercalator detection system can include a filtration unit a control sample conditioner operably coupled with the filtration unit and an analytic unit operably coupled with the filtration unit and control sample conditioner and having an electronic chemical array (ECA) reaction component. A data processing unit is operably coupled with the analytic unit and configured to compare and determine a difference between electronic data of a test sample and a conditioned control sample from the ECA reaction component. The difference provides an indication of whether or not a DNA intercalator is present in the test sample.

Abstract: A fingerprint authentication apparatus and a fingerprint authentication are provided. The fingerprint authentication apparatus is configured to prevent infection from viruses or bacteria and quickly and accurately perform fingerprint authentication. The fingerprint authentication apparatus includes an irradiation section that irradiates a mounting section when a finger is not detected to prevent infection.

Abstract: A fingerprint authentication apparatus and a fingerprint authentication are provided. The fingerprint authentication apparatus is configured to prevent infection from viruses or bacteria and quickly and accurately perform fingerprint authentication. The fingerprint authentication apparatus includes an irradiation section that irradiates a mounting section when a finger is not detected to prevent infection.

Abstract: An enzyme electrode that enables rapid degradation of bisphenol-A (BPA) in a contaminated sample and/or monitoring of BPA concentration in a contaminated sample. The enzyme electrode includes a working electrode having one or more selected enzymes that are capable of degrading BPA linked to the working electrode. The selected enzymes linked to the working electrode are capable of degrading BPA at an enhanced rate in response to an applied voltage. The electrode can be used to monitor BPA concentration in a contaminated sample by measuring current flow through the electrode in response to an applied voltage.

Abstract: A fingerprint authentication apparatus and a fingerprint authentication are provided. The fingerprint authentication apparatus is configured to prevent infection from viruses or bacteria and quickly and accurately perform fingerprint authentication. The fingerprint authentication apparatus includes an irradiation section that irradiates a mounting section when a finger is not detected to prevent infection.

Abstract: A DNA intercalator detection system can include a filtration unit a control sample conditioner operably coupled with the filtration unit and an analytic unit operably coupled with the filtration unit and control sample conditioner and having an electronic chemical array (ECA) reaction component. A data processing unit is operably coupled with the analytic unit and configured to compare and determine a difference between electronic data of a test sample and a conditioned control sample from the ECA reaction component. The difference provides an indication of whether or not a DNA intercalator is present in the test sample.

Abstract: The present invention provides a polynucleotide that not only has a high RNA interference effect on its target gene, but also has a very small risk of causing RNA interference against a gene unrelated to the target gene. A sequence segment conforming to the following rules (a) to (d) is searched from the base sequences of a target gene for RNA interference and, based on the search results, a polynucleotide capable of causing RNAi is designed, synthesized, etc.: (a) The 3? end base is adenine, thymine, or uracil, (b) The 5? end base is guanine or cytosine, (c) A 7-base sequence from the 3? end is rich in one or more types of bases selected from the group consisting of adenine, thymine, and uracil, and (d) The number of bases is within a range that allows RNA interference to occur without causing cytotoxicity.

Abstract: The present invention provides a polynucleotide that not only has a high RNA interference effect on its target gene, but also has a very small risk of causing RNA interference against a gene unrelated to the target gene. A sequence segment conforming to the following rules (a) to (d) is searched from the base sequences of a target gene for RNA interference and, based on the search results, a polynucleotide capable of causing RNAi is designed, synthesized, etc.: (a) The 3? end base is adenine, thymine, or uracil, (b) The 5? end base is guanine or cytosine, (c) A 7-base sequence from the 3? end is rich in one or more types of bases selected from the group consisting of adenine, thymine, and uracil, and (d) The number of bases is within a range that allows RNA interference to occur without causing cytotoxicity.

Abstract: An object of the present invention is to provide use of the KIAA0172 gene in treatment and diagnosis of diseases as well as in pharmaceutical development. An agent for treating cancer which comprises as an active ingredient a polypeptide encoded by the KIAA0172 gene, a partial sequence thereof or a variant thereof; an agent for treating cancer which comprises as an active ingredient an oligonucleotide including the KIAA0172 gene sequence; an agent for detecting cancer which comprises an antibody which recognizes polypeptide encoded by the KIAA0172 gene; an agent for detecting cancer which comprises an oligonucleotide including the KIAA0172 gene sequence; a composition for treating cancer which comprises said agent for treating cancer and a pharmaceutically acceptable carrier; and a composition for detecting cancer which comprises said agent for detecting cancer and a pharmaceutically acceptable carrier.

Abstract: An object of the present invention is to provide use of the KIAA0172 gene in treatment and diagnosis of diseases as well as in pharmaceutical development. An agent for treating cancer which comprises as an active ingredient a polypeptide encoded by the KIAA0172 gene, a partial sequence thereof or a variant thereof; an agent for treating cancer which comprises as an active ingredient an oligonucleotide including the KIAA0172 gene sequence; an agent for detecting cancer which comprises an antibody which recognizes polypeptide encoded by the KIAA0172 gene; an agent for detecting cancer which comprises an oligonucleotide including the KIAA0172 gene sequence; a composition for treating cancer which comprises said agent for treating cancer and a pharmaceutically acceptable carrier; and a composition for detecting cancer which comprises said agent for detecting cancer and a pharmaceutically acceptable carrier.

Abstract: In order to detect the effects of environmental hormones, the effect of chemical substances having estrogen-like activity are detected and evaluated.

Abstract: In order to detect the effects of environmental hormones, the effect of chemical substances having estrogen-like activity are detected and evaluated